Pawel Drapala leads the Manufacturing Science and Technology (MSAT) function at AmplifyBio.

Pawel has extensive experience in the biotech industry, specializing in advanced therapy manufacturing, CMC strategy, tech transfer, supply chain strategy, development and commercialization of groundbreaking cell/gene therapies.

Prior to AmplifyBio, Pawel has held key leadership roles at CRISPR Therapeutics, Tesaro (a GSK company), and Alexion Pharmaceuticals. Notable achievements include full lifecycle progression, approval and commercialization of CASGEVY (exagamglogene autotemcel), JEMPERLI (dostarlimab), and SOLIRIS (eculizumab).

Pawel holds a Ph.D. in Chemical Engineering from Illinois Institute of Technology, and a B.S. in Chemical Engineering from University of Washington.